Alloreactive T-cell response

Alloreactive T-cell response is a prominent immune phenomenon in which T cells mount vigorous reactions against alloantigens, primarily foreign MHC molecules present on transplanted tissues or cells. These T cells—both CD4+ helper and CD8+ cytotoxic subsets—can directly recognize donor cells (direct pathway), or react to recipient antigen-presenting cells displaying processed donor antigens (indirect pathway)[1][6][5]. The alloreactive response is substantially stronger than conventional antigen responses due to the frequent cross-reactivity of T-cell receptors with non-self MHC, absence of central tolerance to these antigens, and the diversity of TCR recognition[1][3]. Alloreactive T-cell responses mediate acute transplant rejection and chronic graft-versus-host disease, and are central targets of transplantation immunosuppression[6][5][1]. Experimental and clinical strategies aim to monitor, modulate, and selectively suppress these responses to promote graft survival and immune tolerance[2][6]. Alloreactive T cells display unique metabolic profiles and may be susceptible to targeted metabolic inhibition, which is being explored as an adjunct to conventional immunosuppression[4]. Because this entry refers not to a molecular target but to a cellular immune process, it does not conform to the standard structure for therapeutic target databases.

Other names

Alloreactive T cellsAlloreactivityAllogeneic T-cell responseDonor-reactive T-cell response

Immunosuppression (inhibition of T-cell activation, proliferation, or cytokine production) Costimulation blockade (e.g., inhibiting CD28-CD80/86, CD40-CD154 interactions) Metabolic inhibition (targeting glycolysis, oxidative phosphorylation)